Kliiniline küsimus nr 6

Kas ema urogenitaaltrakti mikrobioloogiliste uuringute teostamine võrreldes mitteteostamisega ähvardava enneaegse sünnituse korral mõjutab ema ja lapse tervisetulemit?

Kriitilised tulemusnäitajad: ema ja lapse peamised tervisetulemid

Tõendusmaterjali antud küsimuse kohta, mis käsitleks mikrobioloogilisi uuringuid just konkreetselt ähvardava enneaegse sünnitusega naistel, mitte skriiningut varasema raseduse ajal, on vähe.

Ravijuhendid

Kokkuvõte: Leidsin kolm ravijuhendit, mis käsitlevad urogenitaaltrakti mikrobioloogiliste uuringute teostamist ähvardava EA sünnituse korral.

Queenslandi RJ soovitab võtta kõrge tupe bakteriaalse külvi, lisaks kombineeritud tupe ja rektumi külvi GBS kandluse tuvastamiseks ning uriini bakteriaalse külvi. ICSI RJ soovitab kaaluda analüüside võtmist gonorröa, klamüüdia, bakteriaalse vaginoosi ja GBS tuvastamiseks ning soovitab võtta uriinianalüüsi ja külvi. Mõlemast ravijuhenditest ei selgu nende soovituste tase ning soovituste järel puuduvad viited, seega pole tõendusmaterjali tugevus täpselt teada.

CDC RJ soovitab ähvardava EA sünnituse või PPROM-i korral skriinida naisi GBS kandluse suhtes, võttes külvi tupe alumisest osast ja rektumist (soovituse tase AII).

Ravijuhend	Viide
 Sterile speculum examination to: Collect high vaginal swab for microscopy culture and sensitivity (MC&S) Collect combined low vaginal and anorectal swab for Group B streptococcus (GBS) Insert swab 2 cm into vagina and then insert same swab 1 cm into anus Midstream specimen of urine for bacteriology (MC&S) (<i>Ei selgu, mis tõendusmaterjalil need soovitused põhinevad, kuna soovituste taga pole viiteid</i>) 	Queensland Clinical Guidelines. Preterm labour and birth. 2014.
 Consider samples for gonorrhea, chlamydia, wet prep for bacterial vaginosis, group B streptococcus (GBS). Obtain urinalysis, urine culture. (Klamüüdia soovitus põhineb madala kvaliteediga tõendusmaterjalil [Andrews, 2000]; ülejäänu kohta ei selgu, millel soovitus põhineb, kuna soovituste taga pole viiteid) 	Creedon D, Akkerman D, Atwood L, Bates L, Harper C, Levin A, McCall C, Peterson D, Rose C, Setterlund L, Walkes B, Wingeier R. Institute for Clinical Systems Improvement. Management of Labor. Updated March 2013.

The following are law components of threatened protony delivery	Contons for Discoss
The following are key components of ulreatened preterm derivery	Centers for Disease
GBS management:	Control and Prevention.
• Women admitted with signs and symptoms of labor	Prevention of
or with rupture of membranes at <37 weeks and 0 days' gestation	Perinatal Group B
should be screened for GBS colonization at hospital admission	Streptococcal Disease
unless a vaginal-rectal GBS screen was performed within the	Revised Guidelines
preceding 5 weeks (AII - Evidence from at least one well-	from CDC, 2010.
designed clinical trial without randomization, cohort or case-	MMWR 2010;59(No.
controlled analytic studies (preferably from more than one center),	RR-10):15-17.
multiple time-series studies, dramatic results from uncontrolled	
studies, or some evidence from laboratory experiments)	
• Swab the lower vagina (vaginal introitus) followed	
by the rectum (i.e. insert swah through the anal sphincter) using	
the same such or two different suchs Corviced periods	
nerizatel or perizael speciment, are not accentable, and a	
perfectation permean specifients are not acceptable, and a	
speculum should not be used for culture collection.	
Euroopa konsensus GBS osas: In the case of women admitted	Renzo GCD, Melin P,
with signs of threatened preterm delivery or preterm	Berardi A, Blennow M,
premature rupture of membranes (pPROM), assessing whether	Carbonell-Estrany X,
preterm labor or rupture of membranes will result in preterm	Donzelli GP, et al.
delivery can be difficult; therefore GBS PCR testing should be	Intrapartum GBS
performed on a vaginal rectal sample to evaluate GBS	screening and
colonization which is then considered valid for 5 weeks. Patient	antibiotic prophylaxis:
should be regularly assessed for progression to true labor and	a European consensus
IAP should be given to patients with a positive GBS screening	conference. The Journal
when entering in true labor. If a woman has not yet delivered 5	of Maternal-Fetal &
weaks after a pagetive veginal restal GPS NAAT testing she	
weeks allel a liegalive vagiliai-lectal ODS INAAT testilig, she	Neonatal Medicine.
should be re-screened to re-evaluate GBS colonization.	Neonatal Medicine. 2015:28(7):766–82.
should be re-screened to re-evaluate GBS colonization. Administration of IAP in patients in threatened preterm delivery	Neonatal Medicine. 2015;28(7):766–82.
should be re-screened to re-evaluate GBS colonization. Administration of IAP in patients in threatened preterm delivery should be weighed against exposing patients in false labor to	Neonatal Medicine. 2015;28(7):766–82.
should be re-screened to re-evaluate GBS to the should be re-screened to re-evaluate GBS colonization. Administration of IAP in patients in threatened preterm delivery should be weighed against exposing patients in false labor to antibiotics with potential detrimental effects as	Neonatal Medicine. 2015;28(7):766–82.
should be re-screened to re-evaluate GBS to the should be re-screened to re-evaluate GBS colonization. Administration of IAP in patients in threatened preterm delivery should be weighed against exposing patients in false labor to antibiotics with potential detrimental effects as	Neonatal Medicine. 2015;28(7):766–82.
should be re-screened to re-evaluate GBS to the should be re-screened to re-evaluate GBS colonization. Administration of IAP in patients in threatened preterm delivery should be weighed against exposing patients in false labor to antibiotics with potential detrimental effects as demonstrated by the ORACLE II study [122].	Neonatal Medicine. 2015;28(7):766–82.
should be re-screened to re-evaluate GBS to the should be re-screened to re-evaluate GBS colonization. Administration of IAP in patients in threatened preterm delivery should be weighed against exposing patients in false labor to antibiotics with potential detrimental effects as demonstrated by the ORACLE II study [122]. As the effectiveness of GBS screening strategy depends	Neonatal Medicine. 2015;28(7):766–82.
should be re-screened to re-evaluate GBS to the should be re-screened to re-evaluate GBS colonization. Administration of IAP in patients in threatened preterm delivery should be weighed against exposing patients in false labor to antibiotics with potential detrimental effects as demonstrated by the ORACLE II study [122]. As the effectiveness of GBS screening strategy depends on timely administration of IAP, the rapid NAAT test should be	Neonatal Medicine. 2015;28(7):766–82.
should be re-screened to re-evaluate GBS to the should be re-screened to re-evaluate GBS colonization. Administration of IAP in patients in threatened preterm delivery should be weighed against exposing patients in false labor to antibiotics with potential detrimental effects as demonstrated by the ORACLE II study [122]. As the effectiveness of GBS screening strategy depends on timely administration of IAP, the rapid NAAT test should be performed quickly after the specimen collection to avoid delay in	Neonatal Medicine. 2015;28(7):766–82.
should be re-screened to re-evaluate GBS NAAAT testing, she should be re-screened to re-evaluate GBS colonization. Administration of IAP in patients in threatened preterm delivery should be weighed against exposing patients in false labor to antibiotics with potential detrimental effects as demonstrated by the ORACLE II study [122]. As the effectiveness of GBS screening strategy depends on timely administration of IAP, the rapid NAAT test should be performed quickly after the specimen collection to avoid delay in results and the start of IAP. Thus, the rapid NAAT test should be	Neonatal Medicine. 2015;28(7):766–82.
should be re-screened to re-evaluate GBS to the AAT testing, she Administration of IAP in patients in threatened preterm delivery should be weighed against exposing patients in false labor to antibiotics with potential detrimental effects as demonstrated by the ORACLE II study [122]. As the effectiveness of GBS screening strategy depends on timely administration of IAP, the rapid NAAT test should be performed quickly after the specimen collection to avoid delay in results and the start of IAP. Thus, the rapid NAAT test should be implemented at the point of care, in delivery settings except if the	Neonatal Medicine. 2015;28(7):766–82.
should be re-screened to re-evaluate GBS to the should be re-screened to re-evaluate GBS colonization. Administration of IAP in patients in threatened preterm delivery should be weighed against exposing patients in false labor to antibiotics with potential detrimental effects as demonstrated by the ORACLE II study [122]. As the effectiveness of GBS screening strategy depends on timely administration of IAP, the rapid NAAT test should be performed quickly after the specimen collection to avoid delay in results and the start of IAP. Thus, the rapid NAAT test should be implemented at the point of care, in delivery settings except if the premises	Neonatal Medicine. 2015;28(7):766–82.
should be re-screened to re-evaluate GBS to the should be re-screened to re-evaluate GBS colonization. Administration of IAP in patients in threatened preterm delivery should be weighed against exposing patients in false labor to antibiotics with potential detrimental effects as demonstrated by the ORACLE II study [122]. As the effectiveness of GBS screening strategy depends on timely administration of IAP, the rapid NAAT test should be performed quickly after the specimen collection to avoid delay in results and the start of IAP. Thus, the rapid NAAT test should be implemented at the point of care, in delivery settings except if the premises of laboratory are adjacent.	Neonatal Medicine. 2015;28(7):766–82.
should be re-screened to re-evaluate GBS to the should be re-screened to re-evaluate GBS colonization. Administration of IAP in patients in threatened preterm delivery should be weighed against exposing patients in false labor to antibiotics with potential detrimental effects as demonstrated by the ORACLE II study [122]. As the effectiveness of GBS screening strategy depends on timely administration of IAP, the rapid NAAT test should be performed quickly after the specimen collection to avoid delay in results and the start of IAP. Thus, the rapid NAAT test should be implemented at the point of care, in delivery settings except if the premises of laboratory are adjacent. Physicians, midwives or other qualified caregivers	Neonatal Medicine. 2015;28(7):766–82.
should be re-screened to re-evaluate GBS totAAT testing, she should be re-screened to re-evaluate GBS colonization. Administration of IAP in patients in threatened preterm delivery should be weighed against exposing patients in false labor to antibiotics with potential detrimental effects as demonstrated by the ORACLE II study [122]. As the effectiveness of GBS screening strategy depends on timely administration of IAP, the rapid NAAT test should be performed quickly after the specimen collection to avoid delay in results and the start of IAP. Thus, the rapid NAAT test should be implemented at the point of care, in delivery settings except if the premises of laboratory are adjacent. Physicians, midwives or other qualified caregivers should collect vaginal specimen for rapid GBS testing	Neonatal Medicine. 2015;28(7):766–82.
should be re-screened to re-evaluate GBS total in testing, she should be re-screened to re-evaluate GBS colonization. Administration of IAP in patients in threatened preterm delivery should be weighed against exposing patients in false labor to antibiotics with potential detrimental effects as demonstrated by the ORACLE II study [122]. As the effectiveness of GBS screening strategy depends on timely administration of IAP, the rapid NAAT test should be performed quickly after the specimen collection to avoid delay in results and the start of IAP. Thus, the rapid NAAT test should be implemented at the point of care, in delivery settings except if the premises of laboratory are adjacent. Physicians, midwives or other qualified caregivers should collect vaginal specimen for rapid GBS testing at the beginning of signs and symptoms of labor.	Neonatal Medicine. 2015;28(7):766–82.
should be re-screened to re-evaluate GBS totAAT testing, she should be re-screened to re-evaluate GBS colonization. Administration of IAP in patients in threatened preterm delivery should be weighed against exposing patients in false labor to antibiotics with potential detrimental effects as demonstrated by the ORACLE II study [122]. As the effectiveness of GBS screening strategy depends on timely administration of IAP, the rapid NAAT test should be performed quickly after the specimen collection to avoid delay in results and the start of IAP. Thus, the rapid NAAT test should be implemented at the point of care, in delivery settings except if the premises of laboratory are adjacent. Physicians, midwives or other qualified caregivers should collect vaginal specimen for rapid GBS testing at the beginning of signs and symptoms of labor. For patients entering labor (either term or preterm), only	Neonatal Medicine. 2015;28(7):766–82.
should be re-screened to re-evaluate GBS colonization. Administration of IAP in patients in threatened preterm delivery should be weighed against exposing patients in false labor to antibiotics with potential detrimental effects as demonstrated by the ORACLE II study [122]. As the effectiveness of GBS screening strategy depends on timely administration of IAP, the rapid NAAT test should be performed quickly after the specimen collection to avoid delay in results and the start of IAP. Thus, the rapid NAAT test should be implemented at the point of care, in delivery settings except if the premises of laboratory are adjacent. Physicians, midwives or other qualified caregivers should collect vaginal specimen for rapid GBS testing at the beginning of signs and symptoms of labor. For patients entering labor (either term or preterm), only secretions from the lower one-third of the vagina should be	Neonatal Medicine. 2015;28(7):766–82.
should be re-screened to re-evaluate GBS to AAAT testing, she should be re-screened to re-evaluate GBS colonization. Administration of IAP in patients in threatened preterm delivery should be weighed against exposing patients in false labor to antibiotics with potential detrimental effects as demonstrated by the ORACLE II study [122]. As the effectiveness of GBS screening strategy depends on timely administration of IAP, the rapid NAAT test should be performed quickly after the specimen collection to avoid delay in results and the start of IAP. Thus, the rapid NAAT test should be implemented at the point of care, in delivery settings except if the premises of laboratory are adjacent. Physicians, midwives or other qualified caregivers should collect vaginal specimen for rapid GBS testing at the beginning of signs and symptoms of labor. For patients entering labor (either term or preterm), only secretions from the lower one-third of the vagina should be swabbed without using a speculum. Sampling the rectum site	Neonatal Medicine. 2015;28(7):766–82.
should be re-screened to re-evaluate GBS totAAAT testing, she should be re-screened to re-evaluate GBS colonization. Administration of IAP in patients in threatened preterm delivery should be weighed against exposing patients in false labor to antibiotics with potential detrimental effects as demonstrated by the ORACLE II study [122]. As the effectiveness of GBS screening strategy depends on timely administration of IAP, the rapid NAAT test should be performed quickly after the specimen collection to avoid delay in results and the start of IAP. Thus, the rapid NAAT test should be implemented at the point of care, in delivery settings except if the premises of laboratory are adjacent. Physicians, midwives or other qualified caregivers should collect vaginal specimen for rapid GBS testing at the beginning of signs and symptoms of labor. For patients entering labor (either term or preterm), only secretions from the lower one-third of the vagina should be swabbed without using a speculum. Sampling the rectum site is not warranted for intrapartum GBS screening.	Neonatal Medicine. 2015;28(7):766–82.
should be re-screened to re-evaluate GBS colonization. Administration of IAP in patients in threatened preterm delivery should be weighed against exposing patients in false labor to antibiotics with potential detrimental effects as demonstrated by the ORACLE II study [122]. As the effectiveness of GBS screening strategy depends on timely administration of IAP, the rapid NAAT test should be performed quickly after the specimen collection to avoid delay in results and the start of IAP. Thus, the rapid NAAT test should be implemented at the point of care, in delivery settings except if the premises of laboratory are adjacent. Physicians, midwives or other qualified caregivers should collect vaginal specimen for rapid GBS testing at the beginning of signs and symptoms of labor. For patients entering labor (either term or preterm), only secretions from the lower one-third of the vagina should be swabbed without using a speculum. Sampling the rectum site is not warranted for intrapartum GBS screening. Swabbing both the lower vagina and the rectum is	Neonatal Medicine. 2015;28(7):766–82.
should be re-screened to re-evaluate GBS colonization. Administration of IAP in patients in threatened preterm delivery should be weighed against exposing patients in false labor to antibiotics with potential detrimental effects as demonstrated by the ORACLE II study [122]. As the effectiveness of GBS screening strategy depends on timely administration of IAP, the rapid NAAT test should be performed quickly after the specimen collection to avoid delay in results and the start of IAP. Thus, the rapid NAAT test should be implemented at the point of care, in delivery settings except if the premises of laboratory are adjacent. Physicians, midwives or other qualified caregivers should collect vaginal specimen for rapid GBS testing at the beginning of signs and symptoms of labor. For patients entering labor (either term or preterm), only secretions from the lower one-third of the vagina should be swabbed without using a speculum. Sampling the rectum site is not warranted for intrapartum GBS screening. Swabbing both the lower vagina and the rectum is warranted only for women with threatened preterm delivery	Neonatal Medicine. 2015;28(7):766–82.

are not already entering labor	

Süstemaatilised ülevaated

Kokkuvõte: Süstemaatiline ülevaade (Valkenburg-van den Berg et al., 2009), mis kaasas 20 uuringut (16 kohort- ja läbilõikeuuringut, 4 juht-kontrolluuringut, 45888 patsienti), hindas ema GBS kolonisatsiooni ja enneaegse sünnituse vahelist seost. Uuringud erinesid üksteisest meetodite ja GBS esinemuse osas. Ei leitud olulist seost rasedusaegse GBS kandluse ja enneaegse sünnituse vahel. Läbilõikeuuringud ja juht-kontrolluuringud näitasid, et enneaegse sünnitusega naistel esines sagedamini GBS kandlus.

Metaanalüüs (Leitich et al., 2007), mis hõlmas endas 32 uuringut (kohortuuringud või RCT kontrollgrupid, 30518 patsienti), hindas bakteriaalset vaginoosi kui riskifaktorit rasedusega seotud ebasoodsa tervisetulemi tekkeks. Ähvardava enneaegse sünnitusega patsientidel seostus bakteriaalse vaginoosi esinemine enneaegse sünnituse riski üle kahe kordse tõusuga (OR: 2.38, 95% CI: 1.02-5.58). Bakteriaalse vaginoosi ja neonataalsete infektsioonide ega perinataalse suremuse osas ei leitud olulist seost.

Brocklehurst 2013 SR: Asümptomaatilise bakteriaalse vaginoosi ravi ei vähenda enneaegse sünnituse riski.

Smaill 2007 SR: Aümptomaatilise bakteriuuria korral on AB ravi efektiivne, väheneb risk püelonefriidi tekkeks.

Süst. ülevaade/meta-analüüs	Viide
Süstemaatiline ülevaade: The objective of this review was to	Valkenburg-van den Berg,
determine the relationship between maternal colonization with	A.W., Sprij, A.J.,
GBS and preterm delivery. Out of more than 60 full-text	Dekker, F.W., Dörr, P.J.,
articles, 16 follow-up studies and four case control studies were	Kanhai, H.H.H., 2009 .
included in this review. Follow-up studies were divided into	Association between
'cohort studies,' in which cultures were taken early in pregnancy	colonization with
and which reported on pregnancy outcome, and 'cross-sectional	Group B Streptococcus
studies', in which cultures were collected during delivery.	and preterm delivery: a
Studies differed widely in methods, validity score, and GBS	systematic review. Acta
prevalence. The combined estimate from a random effect meta-	Obstet Gynecol Scand
analysis of the 11 cohort studies was 1.06 (95% confidence	88, 958–967.
intervals (CI) 0.95-1.19) and for the five cross-sectional studies	doi:10.1080/0001634090
1.75 (95% CI 1.43-2.14). For the case control studies, the pooled	3176800
odds ratio was 1.59 (95% CI 1.03-2.44). This systematic review	
did not show an association between maternal GBS	
colonization during pregnancy and preterm delivery. Cross-	
sectional studies during delivery and case control studies	
showed positive GBS cultures more frequently in patients with	
preterm delivery.	
Meta-analüüs: We updated a previously published meta-analysis	Leitich, H., Kiss, H.,
to evaluate bacterial vaginosis (BV) and intermediate vaginal	2007. Asymptomatic
flora as risk factors for adverse pregnancy outcome. Selection	bacterial vaginosis and
criteria were original, published, English-language reports of	intermediate flora as
cohort studies or control groups of clinical trials including	risk factors for adverse
women <37 weeks' gestation with intact amniotic membranes. All	pregnancy outcome.

women had to be screened for BV, diagnosed either by clinical	Best Pract Res Clin
criteria or by criteria based on Gram-stain findings. Outcomes	Obstet Gynaecol 21,
were preterm delivery, late miscarriages, maternal or neonatal	375–390.
infections, and perinatal mortality. Fourteen new studies with	doi:10.1016/j.bpobgyn.2
results for 10,286 patients were included, so that results for 30,518	006.12.005
patients in 32 studies were available for this meta-analysis. BV	
more than doubled the risk of preterm delivery in	
asymptomatic patients (OR: 2.16, 95% CI: 1.56-3.00) and in	
patients with symptoms of preterm labor (OR: 2.38, 95% CI:	
1.02-5.58). BV also significantly increased the risk of late	
miscarriages (OR: 6.32, 95% CI: 3.65-10.94) and maternal	
infection (OR: 2.53, 95% CI 1.26-5.08) in asymptomatic	
patients. No significant results were calculated for the	
outcomes of neonatal infection or perinatal mortality. Also,	
intermediate vaginal flora was not significantly associated with	
any outcome included.	
In this analysis BV was significantly associated with preterm	
delivery in symptomatic patients admitted with a diagnosis of	
preterm labor, and the test of heterogeneity was not significant.	
Thus, BV as a marker of intrauterine infection may help to	
identify patients with 'true' preterm labor, who subsequently	
deliver preterm.	
The results of this meta-analysis confirm that BV is a risk factor	
for preterm delivery and maternal infectious morbidity and a	
strong risk factor for late miscarriage.	
Bakteriaalse vaginoosi ravi: Objectives: To assess the effects of	Brocklehurst P, Gordon
Bakteriaalse vaginoosi ravi: Objectives: To assess the effects of antibiotic treatment of bacterial vaginosis in pregnancy. Selection	Brocklehurst P, Gordon A, Heatley E, Milan SJ.
Bakteriaalse vaginoosi ravi: Objectives: To assess the effects of antibiotic treatment of bacterial vaginosis in pregnancy. Selection criteria: Randomised trials comparing antibiotic treatment with	Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating
Bakteriaalse vaginoosi ravi: Objectives: To assess the effects of antibiotic treatment of bacterial vaginosis in pregnancy. Selection criteria: Randomised trials comparing antibiotic treatment with placebo or no treatment, or comparing two or more antibiotic	Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in
Bakteriaalse vaginoosi ravi: Objectives: To assess the effects of antibiotic treatment of bacterial vaginosis in pregnancy. Selection criteria: Randomised trials comparing antibiotic treatment with placebo or no treatment, or comparing two or more antibiotic regimens in pregnant women with bacterial vaginosis or	Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane
Bakteriaalse vaginoosi ravi: Objectives: To assess the effects of antibiotic treatment of bacterial vaginosis in pregnancy. Selection criteria: Randomised trials comparing antibiotic treatment with placebo or no treatment, or comparing two or more antibiotic regimens in pregnant women with bacterial vaginosis or intermediate vaginal flora whether symptomatic or asymptomatic	Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev.
Bakteriaalse vaginoosi ravi: Objectives: To assess the effects of antibiotic treatment of bacterial vaginosis in pregnancy. Selection criteria: Randomised trials comparing antibiotic treatment with placebo or no treatment, or comparing two or more antibiotic regimens in pregnant women with bacterial vaginosis or intermediate vaginal flora whether symptomatic or asymptomatic and detected through screening.	Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2013;1:CD000262.
Bakteriaalse vaginoosi ravi: Objectives: To assess the effects of antibiotic treatment of bacterial vaginosis in pregnancy. Selection criteria: Randomised trials comparing antibiotic treatment with placebo or no treatment, or comparing two or more antibiotic regimens in pregnant women with bacterial vaginosis or intermediate vaginal flora whether symptomatic or asymptomatic and detected through screening. Main results: We included 21 trials of good quality, involving	Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2013;1:CD000262.
Bakteriaalse vaginoosi ravi: Objectives: To assess the effects of antibiotic treatment of bacterial vaginosis in pregnancy. Selection criteria: Randomised trials comparing antibiotic treatment with placebo or no treatment, or comparing two or more antibiotic regimens in pregnant women with bacterial vaginosis or intermediate vaginal flora whether symptomatic or asymptomatic and detected through screening. Main results: We included 21 trials of good quality, involving 7847 women diagnosed with bacterial vaginosis or intermediate	Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2013;1:CD000262.
 Bakteriaalse vaginoosi ravi: Objectives: To assess the effects of antibiotic treatment of bacterial vaginosis in pregnancy. Selection criteria: Randomised trials comparing antibiotic treatment with placebo or no treatment, or comparing two or more antibiotic regimens in pregnant women with bacterial vaginosis or intermediate vaginal flora whether symptomatic or asymptomatic and detected through screening. Main results: We included 21 trials of good quality, involving 7847 women diagnosed with bacterial vaginosis or intermediate vaginal flora. Treatment did not reduce the risk of PTB before 	Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2013;1:CD000262.
 Bakteriaalse vaginoosi ravi: Objectives: To assess the effects of antibiotic treatment of bacterial vaginosis in pregnancy. Selection criteria: Randomised trials comparing antibiotic treatment with placebo or no treatment, or comparing two or more antibiotic regimens in pregnant women with bacterial vaginosis or intermediate vaginal flora whether symptomatic or asymptomatic and detected through screening. Main results: We included 21 trials of good quality, involving 7847 women diagnosed with bacterial vaginosis or intermediate vaginal flora. Treatment did not reduce the risk of PTB before 37 weeks (average RR 0.88; 95% CI 0.71 to 1.09; 13 trials, 	Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2013;1:CD000262.
Bakteriaalse vaginoosi ravi: Objectives: To assess the effects of antibiotic treatment of bacterial vaginosis in pregnancy. Selection criteria: Randomised trials comparing antibiotic treatment with placebo or no treatment, or comparing two or more antibiotic regimens in pregnant women with bacterial vaginosis or intermediate vaginal flora whether symptomatic or asymptomatic and detected through screening. Main results: We included 21 trials of good quality, involving 7847 women diagnosed with bacterial vaginosis or intermediate vaginal flora. Treatment did not reduce the risk of PTB before 37 weeks (average RR 0.88; 95% CI 0.71 to 1.09; 13 trials, 6491 women; randomeffects, $T^2 = 0.06$, $I^2 = 48\%$), or the risk	Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2013;1:CD000262.
Bakteriaalse vaginoosi ravi: Objectives: To assess the effects of antibiotic treatment of bacterial vaginosis in pregnancy. Selection criteria: Randomised trials comparing antibiotic treatment with placebo or no treatment, or comparing two or more antibiotic regimens in pregnant women with bacterial vaginosis or intermediate vaginal flora whether symptomatic or asymptomatic and detected through screening. Main results: We included 21 trials of good quality, involving 7847 women diagnosed with bacterial vaginosis or intermediate vaginal flora. Treatment did not reduce the risk of PTB before 37 weeks (average RR 0.88; 95% CI 0.71 to 1.09; 13 trials, 6491 women; randomeffects, $T^2 = 0.06$, $I^2 = 48\%$), or the risk of preterm prelabour rupture of membranes (RR 0.74; 95%)	Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2013;1:CD000262.
Bakteriaalse vaginoosi ravi: Objectives: To assess the effects of antibiotic treatment of bacterial vaginosis in pregnancy. Selection criteria: Randomised trials comparing antibiotic treatment with placebo or no treatment, or comparing two or more antibiotic regimens in pregnant women with bacterial vaginosis or intermediate vaginal flora whether symptomatic or asymptomatic and detected through screening. Main results: We included 21 trials of good quality, involving 7847 women diagnosed with bacterial vaginosis or intermediate vaginal flora. Treatment did not reduce the risk of PTB before 37 weeks (average RR 0.88; 95% CI 0.71 to 1.09; 13 trials, 6491 women; randomeffects, $T^2 = 0.06$, $I^2 = 48\%$), or the risk of preterm prelabour rupture of membranes (RR 0.74; 95% CI 0.30 to 1.84; two trials, 493 women). It did increase the risk	Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2013;1:CD000262.
Bakteriaalse vaginoosi ravi: Objectives: To assess the effects of antibiotic treatment of bacterial vaginosis in pregnancy. Selection criteria: Randomised trials comparing antibiotic treatment with placebo or no treatment, or comparing two or more antibiotic regimens in pregnant women with bacterial vaginosis or intermediate vaginal flora whether symptomatic or asymptomatic and detected through screening . Main results: We included 21 trials of good quality, involving 7847 women diagnosed with bacterial vaginosis or intermediate vaginal flora. Treatment did not reduce the risk of PTB before 37 weeks (average RR 0.88; 95% CI 0.71 to 1.09; 13 trials, 6491 women; randomeffects, T² = 0.06, I² = 48%), or the risk of preterm prelabour rupture of membranes (RR 0.74; 95% CI 0.30 to 1.84; two trials, 493 women). It did increase the risk of side-effects sufficient to stop or change treatment (RR 1.66;	Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2013;1:CD000262.
Bakteriaalse vaginoosi ravi: Objectives: To assess the effects of antibiotic treatment of bacterial vaginosis in pregnancy. Selection criteria: Randomised trials comparing antibiotic treatment with placebo or no treatment, or comparing two or more antibiotic regimens in pregnant women with bacterial vaginosis or intermediate vaginal flora whether symptomatic or asymptomatic and detected through screening. Main results: We included 21 trials of good quality, involving 7847 women diagnosed with bacterial vaginosis or intermediate vaginal flora. Treatment did not reduce the risk of PTB before 37 weeks (average RR 0.88; 95% CI 0.71 to 1.09; 13 trials, 6491 women; randomeffects, $T^2 = 0.06$, $I^2 = 48\%$), or the risk of preterm prelabour rupture of membranes (RR 0.74; 95% CI 0.30 to 1.84; two trials, 493 women). It did increase the risk of side-effects sufficient to stop or change treatment (RR 1.66; 95% CI 1.02 to 2.68; four trials, 2323 women, fixed-effect, I² =	Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2013;1:CD000262.
Bakteriaalse vaginoosi ravi: Objectives: To assess the effects of antibiotic treatment of bacterial vaginosis in pregnancy. Selection criteria: Randomised trials comparing antibiotic treatment with placebo or no treatment, or comparing two or more antibiotic regimens in pregnant women with bacterial vaginosis or intermediate vaginal flora whether symptomatic or asymptomatic and detected through screening. Main results: We included 21 trials of good quality, involving 7847 women diagnosed with bacterial vaginosis or intermediate vaginal flora. Treatment did not reduce the risk of PTB before 37 weeks (average RR 0.88; 95% CI 0.71 to 1.09; 13 trials, 6491 women; randomeffects, T² = 0.06, I² = 48%), or the risk of preterm prelabour rupture of membranes (RR 0.74; 95% CI 0.30 to 1.84; two trials, 493 women). It did increase the risk of side-effects sufficient to stop or change treatment (RR 1.66; 95% CI 1.02 to 2.68; four trials, 2323 women, fixed-effect, I² = 0%). In this updated review, treatment before 20 weeks' gestation	Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2013;1:CD000262.
Bakteriaalse vaginoosi ravi: Objectives: To assess the effects of antibiotic treatment of bacterial vaginosis in pregnancy. Selection criteria: Randomised trials comparing antibiotic treatment with placebo or no treatment, or comparing two or more antibiotic regimens in pregnant women with bacterial vaginosis or intermediate vaginal flora whether symptomatic or asymptomatic and detected through screening . Main results: We included 21 trials of good quality, involving 7847 women diagnosed with bacterial vaginosis or intermediate vaginal flora. Treatment did not reduce the risk of PTB before 37 weeks (average RR 0.88; 95% CI 0.71 to 1.09; 13 trials, 6491 women; randomeffects, $T^2 = 0.06$, $I^2 = 48\%$), or the risk of preterm prelabour rupture of membranes (RR 0.74; 95% CI 0.30 to 1.84; two trials, 493 women). It did increase the risk of side-effects sufficient to stop or change treatment (RR 1.66; 95% CI 1.02 to 2.68; four trials, 2323 women, fixed-effect, $I^2 = 0\%$). In this updated review, treatment before 20 weeks' gestation did not reduce the risk of PTB less than 37 weeks (average RR	Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2013;1:CD000262.
Bakteriaalse vaginoosi ravi: Objectives: To assess the effects of antibiotic treatment of bacterial vaginosis in pregnancy. Selection criteria: Randomised trials comparing antibiotic treatment with placebo or no treatment, or comparing two or more antibiotic regimens in pregnant women with bacterial vaginosis or intermediate vaginal flora whether symptomatic or asymptomatic and detected through screening . Main results: We included 21 trials of good quality, involving 7847 women diagnosed with bacterial vaginosis or intermediate vaginal flora. Treatment did not reduce the risk of PTB before 37 weeks (average RR 0.88; 95% CI 0.71 to 1.09; 13 trials, 6491 women; randomeffects, $T^2 = 0.06$, $I^2 = 48\%$), or the risk of preterm prelabour rupture of membranes (RR 0.74; 95% CI 0.30 to 1.84; two trials, 493 women). It did increase the risk of side-effects sufficient to stop or change treatment (RR 1.66; 95% CI 1.02 to 2.68; four trials, 2323 women, fixed-effect, $I^2 = 0\%$). In this updated review, treatment before 20 weeks' gestation did not reduce the risk of PTB less than 37 weeks (average RR 0.85; 95% CI 0.62 to 1.17; five trials, 4088 women; random-	Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2013;1:CD000262.
Bakteriaalse vaginoosi ravi: Objectives: To assess the effects of antibiotic treatment of bacterial vaginosis in pregnancy. Selection criteria: Randomised trials comparing antibiotic treatment with placebo or no treatment, or comparing two or more antibiotic regimens in pregnant women with bacterial vaginosis or intermediate vaginal flora whether symptomatic or asymptomatic and detected through screening . Main results: We included 21 trials of good quality, involving 7847 women diagnosed with bacterial vaginosis or intermediate vaginal flora. Treatment did not reduce the risk of PTB before 37 weeks (average RR 0.88; 95% CI 0.71 to 1.09; 13 trials, 6491 women; randomeffects, $T^2 = 0.06$, $I^2 = 48\%$), or the risk of preterm prelabour rupture of membranes (RR 0.74; 95% CI 0.30 to 1.84; two trials, 493 women). It did increase the risk of side-effects sufficient to stop or change treatment (RR 1.66; 95% CI 1.02 to 2.68; four trials, 2323 women, fixed-effect, $I^2 = 0\%$). In this updated review, treatment before 20 weeks' gestation did not reduce the risk of PTB less than 37 weeks (average RR 0.85; 95% CI 0.62 to 1.17; five trials, 4088 women; random-effects, $T^2 = 0.06$, $I^2 = 49\%$). In women with a previous PTB,	Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2013;1:CD000262.
Bakteriaalse vaginoosi ravi: Objectives: To assess the effects of antibiotic treatment of bacterial vaginosis in pregnancy. Selection criteria: Randomised trials comparing antibiotic treatment with placebo or no treatment, or comparing two or more antibiotic regimens in pregnant women with bacterial vaginosis or intermediate vaginal flora whether symptomatic or asymptomatic and detected through screening. Main results: We included 21 trials of good quality, involving 7847 women diagnosed with bacterial vaginosis or intermediate vaginal flora. Treatment did not reduce the risk of PTB before 37 weeks (average RR 0.88; 95% CI 0.71 to 1.09; 13 trials, 6491 women; randomeffects, T² = 0.06, I² = 48%), or the risk of preterm prelabour rupture of membranes (RR 0.74; 95% CI 0.30 to 1.84; two trials, 493 women). It did increase the risk of side-effects sufficient to stop or change treatment (RR 1.66; 95% CI 1.02 to 2.68; four trials, 2323 women, fixed-effect, I² = 0%). In this updated review, treatment before 20 weeks' gestation did not reduce the risk of PTB less than 37 weeks (average RR 0.85; 95% CI 0.62 to 1.17; five trials, 4088 women; random-effects, T² = 0.06, I² = 49%). In women with a previous PTB, treatment did not affect the risk of subsequent PTB (average RR 0.85; 95% CI 0.42 to 1.40 the previous PTB).	Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2013;1:CD000262.
Bakteriaalse vaginoosi ravi: Objectives: To assess the effects of antibiotic treatment of bacterial vaginosis in pregnancy. Selection criteria: Randomised trials comparing antibiotic treatment with placebo or no treatment, or comparing two or more antibiotic regimens in pregnant women with bacterial vaginosis or intermediate vaginal flora whether symptomatic or asymptomatic and detected through screening. Main results: We included 21 trials of good quality, involving 7847 women diagnosed with bacterial vaginosis or intermediate vaginal flora. Treatment did not reduce the risk of PTB before 37 weeks (average RR 0.88; 95% CI 0.71 to 1.09; 13 trials, 6491 women; randomeffects, T² = 0.06, I² = 48%), or the risk of preterm prelabour rupture of membranes (RR 0.74; 95% CI 0.30 to 1.84; two trials, 493 women). It did increase the risk of side-effects sufficient to stop or change treatment (RR 1.66; 95% CI 1.02 to 2.68; four trials, 2323 women, fixed-effect, I² = 0%). In this updated review, treatment before 20 weeks' gestation did not reduce the risk of PTB less than 37 weeks (average RR 0.85; 95% CI 0.62 to 1.17; five trials, 4088 women; randomeffects, T² = 0.06, I² = 49%). In women with a previous PTB, treatment did not affect the risk of subsequent PTB (average RR 0.78; 95% CI 0.42 to 1.48; three trials, 421 women; random-	Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2013;1:CD000262.
Bakteriaalse vaginoosi ravi: Objectives: To assess the effects of antibiotic treatment of bacterial vaginosis in pregnancy. Selection criteria: Randomised trials comparing antibiotic treatment with placebo or no treatment, or comparing two or more antibiotic regimens in pregnant women with bacterial vaginosis or intermediate vaginal flora whether symptomatic or asymptomatic and detected through screening . Main results: We included 21 trials of good quality, involving 7847 women diagnosed with bacterial vaginosis or intermediate vaginal flora. Treatment did not reduce the risk of PTB before 37 weeks (average RR 0.88; 95% CI 0.71 to 1.09; 13 trials, 6491 women; randomeffects, T² = 0.06, I² = 48%), or the risk of preterm prelabour rupture of membranes (RR 0.74; 95% CI 0.30 to 1.84; two trials, 493 women). It did increase the risk of side-effects sufficient to stop or change treatment (RR 1.66; 95% CI 1.02 to 2.68; four trials, 2323 women, fixed-effect, I² = 0%). In this updated review, treatment before 20 weeks' gestation did not reduce the risk of PTB less than 37 weeks (average RR 0.85; 95% CI 0.62 to 1.17; five trials, 4088 women; random-effects, T² = 0.06, I² = 49%). In women with a previous PTB, treatment did not affect the risk of subsequent PTB (average RR 0.78; 95% CI 0.42 to 1.48; three trials, 421 women; random-effects, T² = 0.19, I² = 72%). In women with abnormal vaginal	Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2013;1:CD000262.

reduce the risk of PTB before 37 weeks (RR 0.53; 95% CI 0.34 to	
0.84; two trials, 894 women). Oral antibiotics versus vaginal	
antibiotics did not reduce the risk of PTB (RR 1.09; 95% CI 0.78	
to 1.52; two trials, 264 women). Oral antibiotics had some	
advantage over vaginal antibiotics (whether metronidazole or	
clindamycin) with respect to admission to neonatal unit (RR 0.63;	
95% CI 0.42 to 0.92, one trial, 156 women), prolongation of	
gestational age (days) (MD 9.00; 95% CI 8.20 to 9.80; one trial,	
156 women) and birthweight (grams) (MD 342.13; 95% CI	
293.04 to 391.22; one trial, 156 women). Different frequency of	
dosing of antibiotics was assessed in one small trial and showed	
no significant difference for any outcome assessed.	
Authors' conclusions: Antibiotic treatment can eradicate	
bacterial vaginosis in pregnancy. The overall risk of PTB was	
not significantly reduced. This review provides little evidence	
that screening and treating all pregnant women with bacterial	
vaginosis will prevent PTB and its consequences. When screening	
criteria were broadened to include women with abnormal flora	
there was a 47% reduction in preterm birth however this is	
limited to two included studies	
milited to two mended studies.	
Asümntomaatiline hakteriuuria ja AR ravi: Rackground:	Smaill F. Vazquez, IC
Asymptomatic bacteriuria occurs in 2% to 10% of pregnancies	Antibiotics for
Asymptomatic bacteria docurs in 2% to 10% of pregnancies	Antibiotics for
and it not traated up to slub of mothers will develop acute	
and, if not treated, up to 30% of mothers will develop acute	asymptomatic bootoriurio in
and, if not treated, up to 30% of mothers will develop acute pyelonephritis. Asymptomatic bacteriuria has been associated with low bithwaight and protorm delivery OP IFCTIVES . To	bacteriuria in
and, if not treated, up to 30% of mothers will develop acute pyelonephritis. Asymptomatic bacteriuria has been associated with low birthweight and preterm delivery. OBJECTIVES: To	bacteriuria in pregnancy. Cochrane
and, if not treated, up to 30% of mothers will develop acute pyelonephritis. Asymptomatic bacteriuria has been associated with low birthweight and preterm delivery. OBJECTIVES: To assess the effect of antibiotic treatment for asymptomatic	bacteriuria in pregnancy. Cochrane Database Syst Rev.
and, if not treated, up to 30% of mothers will develop acute pyelonephritis. Asymptomatic bacteriuria has been associated with low birthweight and preterm delivery. OBJECTIVES: To assess the effect of antibiotic treatment for asymptomatic bacteriuria on persistent bacteriuria during pregnancy, the	bacteriuria in pregnancy. Cochrane Database Syst Rev. 2007;(2):CD000490.
and, if not treated, up to 30% of mothers will develop acute pyelonephritis. Asymptomatic bacteriuria has been associated with low birthweight and preterm delivery. OBJECTIVES: To assess the effect of antibiotic treatment for asymptomatic bacteriuria on persistent bacteriuria during pregnancy, the development of pyelonephritis and the risk of low birthweight and	bacteriuria in pregnancy. Cochrane Database Syst Rev. 2007;(2):CD000490.
and, if not treated, up to 30% of mothers will develop acute pyelonephritis. Asymptomatic bacteriuria has been associated with low birthweight and preterm delivery. OBJECTIVES: To assess the effect of antibiotic treatment for asymptomatic bacteriuria on persistent bacteriuria during pregnancy, the development of pyelonephritis and the risk of low birthweight and preterm delivery. Randomized trials comparing antibiotic	bacteriuria in pregnancy. Cochrane Database Syst Rev. 2007;(2):CD000490.
and, if not treated, up to 30% of mothers will develop acute pyelonephritis. Asymptomatic bacteriuria has been associated with low birthweight and preterm delivery. OBJECTIVES: To assess the effect of antibiotic treatment for asymptomatic bacteriuria on persistent bacteriuria during pregnancy, the development of pyelonephritis and the risk of low birthweight and preterm delivery. Randomized trials comparing antibiotic treatment with placebo or no SELECTION CRITERIA:	bacteriuria in pregnancy. Cochrane Database Syst Rev. 2007;(2):CD000490.
and, if not treated, up to 30% of mothers will develop acute pyelonephritis. Asymptomatic bacteriuria has been associated with low birthweight and preterm delivery. OBJECTIVES: To assess the effect of antibiotic treatment for asymptomatic bacteriuria on persistent bacteriuria during pregnancy, the development of pyelonephritis and the risk of low birthweight and preterm delivery. Randomized trials comparing antibiotic treatment with placebo or no SELECTION CRITERIA: treatment in pregnant women with asymptomatic bacteriuria	bacteriuria in pregnancy. Cochrane Database Syst Rev. 2007;(2):CD000490.
and, if not treated, up to 30% of mothers will develop acute pyelonephritis. Asymptomatic bacteriuria has been associated with low birthweight and preterm delivery. OBJECTIVES: To assess the effect of antibiotic treatment for asymptomatic bacteriuria on persistent bacteriuria during pregnancy, the development of pyelonephritis and the risk of low birthweight and preterm delivery. Randomized trials comparing antibiotic treatment with placebo or no SELECTION CRITERIA: treatment in pregnant women with asymptomatic bacteriuria found on antenatal screening. MAIN RESULTS: Fourteen	bacteriuria in pregnancy. Cochrane Database Syst Rev. 2007;(2):CD000490.
and, if not treated, up to 30% of mothers will develop acute pyelonephritis. Asymptomatic bacteriuria has been associated with low birthweight and preterm delivery. OBJECTIVES: To assess the effect of antibiotic treatment for asymptomatic bacteriuria on persistent bacteriuria during pregnancy, the development of pyelonephritis and the risk of low birthweight and preterm delivery. Randomized trials comparing antibiotic treatment with placebo or no SELECTION CRITERIA: treatment in pregnant women with asymptomatic bacteriuria found on antenatal screening. MAIN RESULTS: Fourteen studies were included. Overall the study quality was poor.	bacteriuria in pregnancy. Cochrane Database Syst Rev. 2007;(2):CD000490.
and, if not treated, up to 30% of mothers will develop acute pyelonephritis. Asymptomatic bacteriuria has been associated with low birthweight and preterm delivery. OBJECTIVES: To assess the effect of antibiotic treatment for asymptomatic bacteriuria on persistent bacteriuria during pregnancy, the development of pyelonephritis and the risk of low birthweight and preterm delivery. Randomized trials comparing antibiotic treatment with placebo or no SELECTION CRITERIA: treatment in pregnant women with asymptomatic bacteriuria found on antenatal screening. MAIN RESULTS: Fourteen studies were included. Overall the study quality was poor. Antibiotic treatment compared to placebo or no treatment was	bacteriuria in pregnancy. Cochrane Database Syst Rev. 2007;(2):CD000490.
and, if not treated, up to 30% of mothers will develop acute pyelonephritis. Asymptomatic bacteriuria has been associated with low birthweight and preterm delivery. OBJECTIVES: To assess the effect of antibiotic treatment for asymptomatic bacteriuria on persistent bacteriuria during pregnancy, the development of pyelonephritis and the risk of low birthweight and preterm delivery. Randomized trials comparing antibiotic treatment with placebo or no SELECTION CRITERIA: treatment in pregnant women with asymptomatic bacteriuria found on antenatal screening. MAIN RESULTS: Fourteen studies were included. Overall the study quality was poor. Antibiotic treatment compared to placebo or no treatment was effective in clearing asymptomatic bacteriuria (risk ratio (RR)	bacteriuria in pregnancy. Cochrane Database Syst Rev. 2007;(2):CD000490.
and, if not treated, up to 30% of mothers will develop acute pyelonephritis. Asymptomatic bacteriuria has been associated with low birthweight and preterm delivery. OBJECTIVES: To assess the effect of antibiotic treatment for asymptomatic bacteriuria on persistent bacteriuria during pregnancy, the development of pyelonephritis and the risk of low birthweight and preterm delivery. Randomized trials comparing antibiotic treatment with placebo or no SELECTION CRITERIA: treatment in pregnant women with asymptomatic bacteriuria found on antenatal screening. MAIN RESULTS: Fourteen studies were included. Overall the study quality was poor. Antibiotic treatment compared to placebo or no treatment was effective in clearing asymptomatic bacteriuria (risk ratio (RR) 0.25, 95% confidence interval (CI) 0.14 to 0.48). The incidence	bacteriuria in pregnancy. Cochrane Database Syst Rev. 2007;(2):CD000490.
and, if not treated, up to 30% of mothers will develop acute pyelonephritis. Asymptomatic bacteriuria has been associated with low birthweight and preterm delivery. OBJECTIVES: To assess the effect of antibiotic treatment for asymptomatic bacteriuria on persistent bacteriuria during pregnancy, the development of pyelonephritis and the risk of low birthweight and preterm delivery. Randomized trials comparing antibiotic treatment with placebo or no SELECTION CRITERIA: treatment in pregnant women with asymptomatic bacteriuria found on antenatal screening. MAIN RESULTS: Fourteen studies were included. Overall the study quality was poor. Antibiotic treatment compared to placebo or no treatment was effective in clearing asymptomatic bacteriuria (risk ratio (RR) 0.25, 95% confidence interval (CI) 0.14 to 0.48). The incidence of pyelonephritis was reduced (RR 0.23, 95% CI 0.13 to 0.41).	bacteriuria in pregnancy. Cochrane Database Syst Rev. 2007;(2):CD000490.
and, if not treated, up to 30% of mothers will develop acute pyelonephritis. Asymptomatic bacteriuria has been associated with low birthweight and preterm delivery. OBJECTIVES: To assess the effect of antibiotic treatment for asymptomatic bacteriuria on persistent bacteriuria during pregnancy, the development of pyelonephritis and the risk of low birthweight and preterm delivery. Randomized trials comparing antibiotic treatment with placebo or no SELECTION CRITERIA: treatment in pregnant women with asymptomatic bacteriuria found on antenatal screening. MAIN RESULTS: Fourteen studies were included. Overall the study quality was poor. Antibiotic treatment compared to placebo or no treatment was effective in clearing asymptomatic bacteriuria (risk ratio (RR) 0.25, 95% confidence interval (CI) 0.14 to 0.48). The incidence of pyelonephritis was reduced (RR 0.23, 95% CI 0.13 to 0.41). Antibiotic treatment was also associated with a reduction in	bacteriuria in pregnancy. Cochrane Database Syst Rev. 2007;(2):CD000490.
and, if not treated, up to 30% of mothers will develop acute pyelonephritis. Asymptomatic bacteriuria has been associated with low birthweight and preterm delivery. OBJECTIVES: To assess the effect of antibiotic treatment for asymptomatic bacteriuria on persistent bacteriuria during pregnancy, the development of pyelonephritis and the risk of low birthweight and preterm delivery. Randomized trials comparing antibiotic treatment with placebo or no SELECTION CRITERIA: treatment in pregnant women with asymptomatic bacteriuria found on antenatal screening. MAIN RESULTS: Fourteen studies were included. Overall the study quality was poor. Antibiotic treatment compared to placebo or no treatment was effective in clearing asymptomatic bacteriuria (risk ratio (RR) 0.25, 95% confidence interval (CI) 0.14 to 0.48). The incidence of pyelonephritis was reduced (RR 0.23, 95% CI 0.13 to 0.41). Antibiotic treatment was also associated with a reduction in the incidence of low birthweight babies (RR 0.66, 95% CI 0.49	bacteriuria in pregnancy. Cochrane Database Syst Rev. 2007;(2):CD000490.
and, if not treated, up to 30% of mothers will develop acute pyelonephritis. Asymptomatic bacteriuria has been associated with low birthweight and preterm delivery. OBJECTIVES: To assess the effect of antibiotic treatment for asymptomatic bacteriuria on persistent bacteriuria during pregnancy, the development of pyelonephritis and the risk of low birthweight and preterm delivery. Randomized trials comparing antibiotic treatment with placebo or no SELECTION CRITERIA: treatment in pregnant women with asymptomatic bacteriuria found on antenatal screening. MAIN RESULTS: Fourteen studies were included. Overall the study quality was poor. Antibiotic treatment compared to placebo or no treatment was effective in clearing asymptomatic bacteriuria (risk ratio (RR) 0.25, 95% confidence interval (CI) 0.14 to 0.48). The incidence of pyelonephritis was reduced (RR 0.23, 95% CI 0.13 to 0.41). Antibiotic treatment was also associated with a reduction in the incidence of low birthweight babies (RR 0.66, 95% CI 0.49 to 0.89) but a difference in preterm delivery was not seen.	bacteriuria in pregnancy. Cochrane Database Syst Rev. 2007;(2):CD000490.
and, if not treated, up to 30% of mothers will develop acute pyelonephritis. Asymptomatic bacteriuria has been associated with low birthweight and preterm delivery. OBJECTIVES: To assess the effect of antibiotic treatment for asymptomatic bacteriuria on persistent bacteriuria during pregnancy, the development of pyelonephritis and the risk of low birthweight and preterm delivery. Randomized trials comparing antibiotic treatment with placebo or no SELECTION CRITERIA: treatment in pregnant women with asymptomatic bacteriuria found on antenatal screening. MAIN RESULTS: Fourteen studies were included. Overall the study quality was poor. Antibiotic treatment compared to placebo or no treatment was effective in clearing asymptomatic bacteriuria (risk ratio (RR) 0.25, 95% confidence interval (CI) 0.14 to 0.48). The incidence of pyelonephritis was reduced (RR 0.23, 95% CI 0.13 to 0.41). Antibiotic treatment was also associated with a reduction in the incidence of low birthweight babies (RR 0.66, 95% CI 0.49 to 0.89) but a difference in preterm delivery was not seen. AUTHORS' CONCLUSIONS: Antibiotic treatment is effective	bacteriuria in pregnancy. Cochrane Database Syst Rev. 2007;(2):CD000490.
and, if not treated, up to 30% of mothers will develop acute pyelonephritis. Asymptomatic bacteriuria has been associated with low birthweight and preterm delivery. OBJECTIVES: To assess the effect of antibiotic treatment for asymptomatic bacteriuria on persistent bacteriuria during pregnancy, the development of pyelonephritis and the risk of low birthweight and preterm delivery. Randomized trials comparing antibiotic treatment with placebo or no SELECTION CRITERIA: treatment in pregnant women with asymptomatic bacteriuria found on antenatal screening. MAIN RESULTS: Fourteen studies were included. Overall the study quality was poor. Antibiotic treatment compared to placebo or no treatment was effective in clearing asymptomatic bacteriuria (risk ratio (RR) 0.25, 95% confidence interval (CI) 0.14 to 0.48). The incidence of pyelonephritis was reduced (RR 0.23, 95% CI 0.13 to 0.41). Antibiotic treatment was also associated with a reduction in the incidence of low birthweight babies (RR 0.66, 95% CI 0.49 to 0.89) but a difference in preterm delivery was not seen. AUTHORS' CONCLUSIONS: Antibiotic treatment is effective in reducing the risk of pyelonephritis in pregnancy. A	bacteriuria in pregnancy. Cochrane Database Syst Rev. 2007;(2):CD000490.
and, if not treated, up to 30% of mothers will develop acute pyelonephritis. Asymptomatic bacteriuria has been associated with low birthweight and preterm delivery. OBJECTIVES: To assess the effect of antibiotic treatment for asymptomatic bacteriuria on persistent bacteriuria during pregnancy, the development of pyelonephritis and the risk of low birthweight and preterm delivery. Randomized trials comparing antibiotic treatment with placebo or no SELECTION CRITERIA: treatment in pregnant women with asymptomatic bacteriuria found on antenatal screening. MAIN RESULTS: Fourteen studies were included. Overall the study quality was poor. Antibiotic treatment compared to placebo or no treatment was effective in clearing asymptomatic bacteriuria (risk ratio (RR) 0.25, 95% confidence interval (CI) 0.14 to 0.48). The incidence of pyelonephritis was reduced (RR 0.23, 95% CI 0.13 to 0.41). Antibiotic treatment was also associated with a reduction in the incidence of low birthweight babies (RR 0.66, 95% CI 0.49 to 0.89) but a difference in preterm delivery was not seen . AUTHORS' CONCLUSIONS: Antibiotic treatment is effective in reducing the risk of pyelonephritis in pregnancy. A reduction in low birthweight is consistent with current theories	bacteriuria in pregnancy. Cochrane Database Syst Rev. 2007;(2):CD000490.
and, if not treated, up to 30% of mothers will develop acute pyelonephritis. Asymptomatic bacteriuria has been associated with low birthweight and preterm delivery. OBJECTIVES: To assess the effect of antibiotic treatment for asymptomatic bacteriuria on persistent bacteriuria during pregnancy, the development of pyelonephritis and the risk of low birthweight and preterm delivery. Randomized trials comparing antibiotic treatment with placebo or no SELECTION CRITERIA: treatment in pregnant women with asymptomatic bacteriuria found on antenatal screening. MAIN RESULTS: Fourteen studies were included. Overall the study quality was poor. Antibiotic treatment compared to placebo or no treatment was effective in clearing asymptomatic bacteriuria (risk ratio (RR) 0.25, 95% confidence interval (CI) 0.14 to 0.48). The incidence of pyelonephritis was reduced (RR 0.23, 95% CI 0.13 to 0.41). Antibiotic treatment was also associated with a reduction in the incidence of low birthweight babies (RR 0.66, 95% CI 0.49 to 0.89) but a difference in preterm delivery was not seen . AUTHORS' CONCLUSIONS: Antibiotic treatment is effective in reducing the risk of pyelonephritis in pregnancy. A reduction in low birthweight is consistent with current theories about the role of infection in adverse pregnancy outcomes, but this	bacteriuria in pregnancy. Cochrane Database Syst Rev. 2007;(2):CD000490.
and, if not treated, up to 30% of mothers will develop acute pyelonephritis. Asymptomatic bacteriuria has been associated with low birthweight and preterm delivery. OBJECTIVES: To assess the effect of antibiotic treatment for asymptomatic bacteriuria on persistent bacteriuria during pregnancy, the development of pyelonephritis and the risk of low birthweight and preterm delivery. Randomized trials comparing antibiotic treatment with placebo or no SELECTION CRITERIA: treatment in pregnant women with asymptomatic bacteriuria found on antenatal screening. MAIN RESULTS: Fourteen studies were included. Overall the study quality was poor. Antibiotic treatment compared to placebo or no treatment was effective in clearing asymptomatic bacteriuria (risk ratio (RR) 0.25, 95% confidence interval (CI) 0.14 to 0.48). The incidence of pyelonephritis was reduced (RR 0.23, 95% CI 0.13 to 0.41). Antibiotic treatment was also associated with a reduction in the incidence of low birthweight babies (RR 0.66, 95% CI 0.49 to 0.89) but a difference in preterm delivery was not seen . AUTHORS' CONCLUSIONS: Antibiotic treatment is effective in reducing the risk of pyelonephritis in pregnancy. A reduction in low birthweight is consistent with current theories about the role of infection in adverse pregnancy outcomes, but this association should be interpreted with caution given the poor	bacteriuria in pregnancy. Cochrane Database Syst Rev. 2007;(2):CD000490.
and, if not treated, up to 30% of mothers will develop acute pyelonephritis. Asymptomatic bacteriuria has been associated with low birthweight and preterm delivery. OBJECTIVES: To assess the effect of antibiotic treatment for asymptomatic bacteriuria on persistent bacteriuria during pregnancy, the development of pyelonephritis and the risk of low birthweight and preterm delivery. Randomized trials comparing antibiotic treatment with placebo or no SELECTION CRITERIA: treatment in pregnant women with asymptomatic bacteriuria found on antenatal screening. MAIN RESULTS: Fourteen studies were included. Overall the study quality was poor. Antibiotic treatment compared to placebo or no treatment was effective in clearing asymptomatic bacteriuria (risk ratio (RR) 0.25, 95% confidence interval (CI) 0.14 to 0.48). The incidence of pyelonephritis was reduced (RR 0.23, 95% CI 0.13 to 0.41). Antibiotic treatment was also associated with a reduction in the incidence of low birthweight babies (RR 0.66, 95% CI 0.49 to 0.89) but a difference in preterm delivery was not seen . AUTHORS' CONCLUSIONS: Antibiotic treatment is effective in reducing the risk of pyelonephritis in pregnancy. A reduction in low birthweight is consistent with current theories about the role of infection in adverse pregnancy outcomes, but this association should be interpreted with caution given the poor quality of the included studies.	bacteriuria in pregnancy. Cochrane Database Syst Rev. 2007;(2):CD000490.
and, if not treated, up to 30% of mothers will develop acute pyelonephritis. Asymptomatic bacteriuria has been associated with low birthweight and preterm delivery. OBJECTIVES: To assess the effect of antibiotic treatment for asymptomatic bacteriuria on persistent bacteriuria during pregnancy, the development of pyelonephritis and the risk of low birthweight and preterm delivery. Randomized trials comparing antibiotic treatment with placebo or no SELECTION CRITERIA: treatment in pregnant women with asymptomatic bacteriuria found on antenatal screening. MAIN RESULTS: Fourteen studies were included. Overall the study quality was poor. Antibiotic treatment compared to placebo or no treatment was effective in clearing asymptomatic bacteriuria (risk ratio (RR) 0.25, 95% confidence interval (CI) 0.14 to 0.48). The incidence of pyelonephritis was reduced (RR 0.23, 95% CI 0.13 to 0.41). Antibiotic treatment was also associated with a reduction in the incidence of low birthweight babies (RR 0.66, 95% CI 0.49 to 0.89) but a difference in preterm delivery was not seen . AUTHORS' CONCLUSIONS: Antibiotic treatment is effective in reducing the risk of pyelonephritis in pregnancy. A reduction in low birthweight is consistent with current theories about the role of infection in adverse pregnancy outcomes, but this association should be interpreted with caution given the poor quality of the included studies.	asymptomatic bacteriuria in pregnancy. Cochrane Database Syst Rev. 2007;(2):CD000490.

Üksikuuringud

Kokkuvõte:

Retrospektiivne kohortuuring (Chalermchockchareonkit et al., 2013) leidis, et ähvardava enneaegse sünnitusega naistest 24%-l esines positiivne tupe või uriini külv, kuid statistiliselt olulist erinevust enneaegsete sünnituste osas ei esinenud, mistõttu järeldati, et seesugune skriinimine on kaheldav.

Retrospektiivne juht-kontrolluuring (Andrews et al., 2000) leidis, et naistel, kel 24. rasedusnädalal tuvastati klamüdioos, esines 2-3 kordne enneaegse sünnituse riski tõus.

Prospektiivne kohortuuring (Laxmi et al., 2012) käsitles ähvardava enneaegse sünnitusega rasedate skriinimist bakteriaalse vaginoosi osas. Bakteriaalse vaginoosiga patsientide vastsündinutel esines oluliselt rohkem respiratoorset distressi, vajadust IPPV-ks, intensiivravi osakonda hospitaliseerimisi. Olulist erinevust ei leitud keskmise sünnikaalu, Apgari skoori, neonataalse sepsise, perinataalse suremuse ja sünnitusjärgse palaviku osas.

Kahe randomiseeritud kontrolluuringu sekundaarne analüüs (Tajik et al., 2014) vaatles naisi 34.-37. rasedusnädalas PPROM-iga. Leiti, et kohesest sünnitusest oleks kasu neile naistele, kel on GBS kandlus. GBS positiivsetel naistel esines jälgimistaktika korral kõrge risk varaseks neonataalseks sepsiseks, kuid kui rasedus lõpetati kohe, oli risk oluliselt väiksem. GBS negatiivsetel naistel võiks sünnituse induktsiooniga oodata 37. rasedusnädalani.

Retrospektiivne uuring (Anderson 2007) leidis, et ravimata GBS bakteriuuria seostub koorioamnioniidi tekkega.

Ülzailzuuring	Viido
Tai retrospektiivne kohortuuring: Cultures of genitourinary	halermchockchareonkit,
tract microorganisms have been included in routine evaluation for	A., Phoethong, S.,
all pregnant women who present with presumptive preterm labor.	Ruangvutilert, P.,
However some studies found that this assessment is costly and	Thamkhantho, M.,
adds little value.	2013. Prevalence of
Objective: To determine the proportion of pregnant women	positive culture of
with presumptive preterm labor who had positive culture of	genitourinary tract
genitourinary tract microorganisms and to determine the	microorganisms in
relationship of positive genitourinary infection and pregnancy	pregnant women with
outcomes.	presumptive preterm
Material and method: This retrospective cohort study was	labor. J Med Assoc
performed at Department of Obstetrics and Gynecology, Faculty	Thai 96, 1111–1118.
of Medicine, Siriraj Hospital, Mahidol University. Medical	
records of pregnant women with presumptive preterm labor who	
were admitted in non-private labor room between January 2003	
and December 2008 were reviewed. Characteristics, results of	
vaginal swab culture and urine culture, and clinical outcomes	
were analyzed and reported.	
Results: The prevalence of positive culture of genitourinary tract	
microorganisms in presumptive preterm labor-women (total n =	
704) was 24.3% (95% CI = 21.3-27.6), 22.1% (95% CI = 19.1-	
25.4) of vaginal swab culture and 5.3% (95% CI = 3.8-7.2) of	
urine culture. However only 9.8% were pathologic organisms.	

There were no statistically significant differences in characteristics and rate of preterm labor between women with a positive and a negative culture. Moreover, there were no statistically significant differences in characteristics and preterm birth outcomes between women in both groups. Conclusion: There were no clinical significances of positivity of pathologic bacteria from genitourinary tract as a predictor of preterm delivery and its outcomes. Although the prevalence is quite high, the value of these screenings is still questionable.	
USA retrospektiivne juht-kontrolluuring: Objective: This study was undertaken to determine the association between genitourinary tract infection with Chlamydia trachomatis and spontaneous preterm birth. Study design: Genitourinary tract infection with C trachomatis was determined with a ligase chain reaction assay of voided urine samples collected at 24 weeks' gestation (22 weeks' to 24 weeks 6 days' gestation) and 28 weeks' gestation (27 weeks' to 24 weeks 6 days' gestation). Case patients (spontaneous preterm birth at <37 weeks' gestation; n = 190) and control subjects (delivery at >/=37 weeks' gestation, matched for race, parity, and center; n = 190) were selected from 2929 women enrolled in the Preterm Prediction Study of the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Results: Genitourinary C trachomatis infection (11% overall) was significantly more common among the case patients than among the control subjects at 24 weeks' gestation (15.8% vs 6.3%; P =.003) but not at 28 weeks' gestation (12.6% vs 10.9%; P =.61). Women with chlamydia infection were more likely to have bacterial vaginosis (57.1% vs 32.9%; P =.002) and a short cervical length (=25 mm; 33.0% vs 17.9%; P =.02) but not a body mass<br index <19.8 kg/m(2) (35.0% vs 23.9%; P =.17) or a positive fetal fibronectin test result (7.1% vs 9.5%; P =.62). After adjustment for risk factors for spontaneous preterm birth, women with C trachomatis infection at 24 weeks' gestation were 2 times as likely as uninfected women to have a spontaneous preterm birth at <37 weeks' gestation (odds ratio, 2.2; 95% confidence interval, 1.03-4.78) and 3 times as likely to have a spontaneous preterm birth at <35 weeks' gestation (odds ratio, 3.2; 95% confidence interval, 1.08-9.57). Conclusion: Genitourinary C trachomatis infection at 24 weeks' gestation was associated with a 2-fold to 3-fold increased risk of subsequent spontaneous preterm birth.	Andrews, W.W., Goldenberg, R.L., Mercer, B., Iams, J., Meis, P., Moawad, A., Das, A., Vandorsten, J.P., Caritis, S.N., Thurnau, G., Miodovnik, M., Roberts, J., McNellis, D., 2000. The Preterm Prediction Study: association of second- trimester genitourinary chlamydia infection with subsequent spontaneous preterm birth. Am. J. Obstet. Gynecol. 183, 662–668.
India prospektiivne kohortuuring: Objective: To compare the fetomaternal outcome in women with spontaneous preterm labor, with or without bacterial vaginosis (BV). Methods. One hundred and fifty-two (152 – väike valim) pregnant patients presenting with spontaneous preterm labor between 28 and 35 weeks of gestation were	Laxmi, U., Agrawal, S., Raghunandan, C., Randhawa, V.S., Saili, A., 2012. Association of bacterial vaginosis with adverse

screened for BV using Amsel's criteria and Nugent score, and were divided into two groups of 30 patients each, based on the BV positive or negative screen. Both the groups were followed till puerperium, and the fetal-maternal outcome was studied. The data was analyzed using Chi-square test and Man-Whitney test. Results . BV was detected in 37 out of 152 women with preterm labor (24.34%). There was a significant increase in the incidence of respiratory distress (14% vs. 6%), requirement of intermittent positive pressure ventilation (IPPV) (14% vs. 5%), admission in neonatal intensive care unit (NICU) (15% vs. 6%), and duration of NICU stay 42 days (15% vs. 6%) in patients with BV. No significant difference was found in the mean birth weight, Apgar score, incidence of neonatal sepsis, perinatal mortality, and postpartum fever between the two groups. Conclusions. BV is a risk factor for increased neonatal morbidity. More research is needed for designing appropriate screening and treatment guidelines for prevention of adverse outcomes associated with BV.	fetomaternal outcome in women with spontaneous preterm labor: a prospective cohort study. J. Matern. Fetal. Neonatal. Med. 25, 64–67. doi:10.3109/14767058.2 011.565390
Hollandi 2 RCT-i sekundaarne analüüs: Objective: To investigate whether vaginal Group B Streptococcus (GBS) colonisation or other baseline	Tajik, P., van der Ham, D.P., Zafarmand, M.H., Hof M H P. Morris I
shere to ristics of women with protorm promoture runture of	$\begin{array}{c} \text{HOI, WI.H.F., WIOITIS, J.,} \\ \text{Erangeon MTM} \text{do} \end{array}$
membranes (DDDOM) can bely in identifying subgroups of	Groot CIM Duveket
woman who would banafit from immediate delivery	LI Oudijk MA
Design: Secondary analysis of the DDDOMEXIL trials	J.J., Oudijk, M.A., Willekes, C
Setting Sixty hospitals in the Natherlands	Bloemenkamp
Population: Women with PPROM between 34 and 37 weeks of	K W M Porath M
gestation	K.W.M., Toraul, M., Wojski M. Akerboom
Methods: Random assignment of 723 women to immediate	B M Sikkema I M
delivery or expectant management	Nii Bijvank B. Mulder
Main outcome measures: Early onset neonatal sensis	ALM. Bossuvt. P.M.
Results: Vaginal GBS colonisation status was the only marker	Mol. B.W.L. 2014.
which was significantly associated with the benefit of	Using vaginal Group B
immediate delivery (P for interaction: 0.04). GBS colonisation	Streptococcus
was observed in 14% of women. The risk of early onset	colonisation in women
neonatal sepsis in GBS-positive women was high (15.2%)	with preterm
when they were managed expectantly but this risk was	premature rupture of
reduced to 1.8% with immediate delivery. The early onset	membranes to guide
neonatal sepsis risk was much lower in neonates of GBS-negative	the decision for
women: 2.6% after expectant management and 2.9% with	immediate delivery: a
immediate delivery. We estimated that by inducing labour only in	secondary analysis of
GBS-positive women, there would be a 10.4% increase in term	the PPROMEXIL
delivery rate, while keeping neonatal sepsis and caesarean	trials. BJOG 121,
delivery rates comparable to a strategy of labour induction for all.	1263–1272; discussion
Conclusions: Our post hoc findings suggest that women with	1273.
PROM between 34 and 37 weeks might benefit from	doi:10.1111/1471-
immediate delivery if they have GBS vaginal colonisation,	0528.12889
while in GBS-negative women labour induction could be	
delayed until 37 weeks.	

Retrospektiivne kohortuuring GBS bakteriuuria kohta:	Anderson BL, Simhan
OBJECTIVE: The objective of the study was to determine the	HN, Simons KM,
frequency of adverse pregnancy outcomes in women with	Wiesenfeld HC.
untreated asymptomatic group B beta-hemolytic streptococcal	Untreated
(GBS) bacteriuria during pregnancy. RESULTS: One hundred	asymptomatic group B
twenty-two women with bacteriuria (study group) and 183	streptococcal
women with negative antepartum cultures (controls) were	bacteriuria early in
included. Thirty-one women (10.2%) had chorioamnionitis.	pregnancy and
Untreated GBS bacteriuria was associated with	chorioamnionitis at
chorioamnionitis after controlling for confounding variables,	delivery. Am J Obstet
adjusted odds ratio 7.2 (95% confidence interval 2.4 to 21.2).	Gynecol.
There was also a significant positive rank correlation between	2007;196(6):524.e1-5.
increasing colony count of GBS bacteriuria and increasing grade	
of chorioamnionitis (P = .02). CONCLUSION: Untreated	
antepartum GBS bacteriuria is associated with	
chorioamnionitis.	

Otsingustrateegia kliinilisele küsimusele nr 6: Otsingud Pubmedist ja lisaks oluliste viidete läbivaatamine

Andmebaas	Medline (PUBMED)
Otsingustrateegia:	22.04.15 Searh: ((((((((((pretermbirth*)
	OR preterm labor*) OR preterm labour*)
	OR preterm deliver*) OR premature
	birth*) OR premature labor*) OR
	premature labour*) OR premature
	deliver*) OR preterm premature rupture of
	membranes) OR PPROM)) AND
	(((((((((microscopy) OR microbiology)
	OR (microscopy, Culture and
	Sensitivities)) OR MC AND S) OR swab*)
	OR gonorrhea) OR chlamydia) OR GBS)
	OR urinalysis) OR urogenital infection*)
	OR bacterial vaginosis)
Tulemuste arv	n=775
Ajaline piirang	10 aastat
Muud piirangud	English language, Humans

Leidsin 3 ravijuhendit, 4 süstemaatilist ülevaadet/meta-analüüsi, 2 retrospektiivset uuringut, 1 prospektiivse uuringu